Tin tức & Cập nhật

Potent and selective inhibition of IL-17A by izokibep produced a rapid improvement in disease activity across multiple psoriatic arthritis (PsA) domains, according to preliminary data from a phase IIb/III trial.

Upadacitinib remains effective through 5 years in patients with rheumatoid arthritis (RA) who have inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), with no new safety signals, as shown by the results of the phase III long-term extension (LTE) of SELECT-NEXT.

Tofacitinib demonstrates safety and persistence in patients with psoriatic arthritis (PsA) who are mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs, results of a study have shown.